- CIIX
will diversify revenue streams to investor relations, marketing/sales of
hemp-infused/CBD products in China and the United States
- Company
plans launch of hemp-infused wrinkle cream in China, entering potential
market of nearly 1.4 billion people
- In Q1
FY2020, CIIX sales jumped 174.7 percent to $1,956,960 from prior year;
hemp/CBD products rose 569.2 percent
ChineseInvestors.com
Inc. (OTCQB: CIIX), a leading financial information website for
Chinese-speaking investors in the United States and China, plans to diversify
revenue streams in FY2020. In a letter to shareholders, CIIX CEO Warren Wang
outlined the company’s plans to focus on its core investor-relations business
as well as continue to expand and market its industrial hemp-infused/CBD
products in China and the United States as it eyes greater revenues and profits
(http://ibn.fm/mGUbP).
In the letter, Wang said that CIIX plans to launch a
hemp-infused wrinkle cream cosmetic in China in the near future. He emphasized
that the focus of the company’s efforts in industrial hemp/CBD would be in
China through its subsidiary CBD Biotech Co. Ltd. CIIX has supported its
industrial hemp/CBD product lines in China evidenced by new product launches
and initiatives taken to expand geographically in the Asian market (http://ibn.fm/emkqg).
“As product margins seem to be healthier in this market, the
company’s main focus for its industrial hemp business in FY2020 will be on its
China operations where we have a robust product development pipeline,” said
Wang. The CIIX executive also noted that in China, industrial-hemp extract may
be added to cosmetics, thus opening a potential market of nearly 1.4 billion
people to the company.
Moving forward, CIIX should have an advantage in the
legality/trends of industrial hemp/CBD in other Asian markets because it
already has “feet on the ground” in that part of the world, explained Wang.
“Although the U.S. market has experienced some favorable changes in the law
related to industrial hemp/CBD, there has been some volatility, which can be a
consequence of entering a nascent market,” he said. Consequently, Wang said
that CIIX would invest “conservatively” in its United States hemp/CBD
operation, focusing on organic growth.
Wang also disclosed in the letter that CIIX is in the
process of establishing a “working cooperation” with a private equity firm in
China. “We would expect this relationship to have a positive impact on our
investor relations business globally,” he noted.
In its 8-K filing to the SEC, CIIX reported sharply higher
revenues for Q1 2020, the three months ended August 31, 2019. Sales jumped to
$1,956,960, 174.7 percent higher than the $712,360 reported for the same
quarter the prior year. Hemp- and CBD-product revenues drove that increase with
a contribution of $948,751 for the quarter, a 569.2 percent rise from the
$141,764 in Q1 2019 (http://ibn.fm/QjZSW).
CIIX’s core investor-relations business generated $821,361
in Q1 2020, a 200 percent improvement over the $271,248 reported the same
period the prior year. CIIX has refocused and grown its core business.
The Q1 2020 performance continued growth reported earlier as
CIIX recorded sharp gains of 175 percent year-over-year for its FY2019, ended
in May 2019. That rise was generated by FY2019 sales of $6,476,442 compared to
$2,353,331 in FY2018, according to its 10-K SEC filing (http://ibn.fm/di0xI). The
increase was driven by industrial-hemp and CBD-liquor product sales of
$4,189,935 in FY2019 compared to $378,984 in FY2018 (http://ibn.fm/l8Fl1). Investor
relations, a core business, generated gains as well. Its sales were $1,336,402
in FY2019 compared to $968,282 the prior year.
CIIX offers its audience of Chinese-speaking investors
real-time market commentary, analysis and educational-related services in
Chinese character language sets.
For more information, visit the company’s website at www.ChineseInvestors.com
NOTE TO INVESTORS: The latest news and updates
relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
